evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,097 questions · 3,266 findings · 631 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 430 · 13.2%GRADE not reported 193 · 5.9%Very low 995 · 30.5%Low 904 · 27.7%Moderate 591 · 18.1%High 153 · 4.7%

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… may leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with placebo after chemotherapy (maintenance therapy) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Mobility training vs control: subgroups with or without cognitive impairments

Level of functioning · older people living in the community with frailty
2 findings from 1 review

Mobility training vs control: subgroups with or without cognitive impairments

Mobility · older people living in the community with frailty
2 findings from 1 review